HartRGPearceLAAguilarMI. Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med2007; 146:857–67.
2.
Diener H-C., and the Executive Steering Committee on behalf of the SPORTIF III and V Investigators. Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation. Pooled analysis from the SPORTIF III and V studies. Cerebrovasc Dis2006; 21:279–93.
3.
InvestigatorsAMADEUSBousserMGBouthierJ. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation – a randomised, open-label, non-inferiority trial. Lancet2008; 371:315–21.
4.
Connolly SJ, Ezekowitz MD, Yusuf S et al., and the RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med2009; 361:1139–51.
5.
GrossPLWeitzJI. New antithrombotic drugs. Clin Pharmacol Therapeutics2009; 86:139–46.
